<img src="https://ml.globenewswire.com/Resource/Download/7fa09722-2ef8-49fc-bc24-6b150093f8ba?size=2" nborder="0" align="left" hspace="5" vspace="5" title="MBRX_Logo.png" alt="Moleculin Biotech, Inc."/>- Access the segment <a href="https://www.globenewswire.com/Tracker?data=m3wvkghcJspr424sMTW5PyO_mO_W69Kzvf8P6gK7hkMRSxjgV8Zwd3iomNTJU5yoU3n-pcVZWzfJHwYOognGD67MrwE78eAHxmL5WI0UCHo=" rel="nofollow" target="_blank" title="">here</a> HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a <a href="https://www.globenewswire.com/Tracker?data=Vcql5BjsEzpigwdxjvW8ZDYrMcMk90phQbNiLmCsW3b4QWqyoEt4AylXFw5XAdt3rgQLUJMZeFnrFkxkM8Tex3hCgYfg2bIYmvj4CojOrH18_fLlcoFQIqszZBXzTj6qmoqeYy0eo1slFxG96mYPvQ==" rel="nofollow" target="_blank" title="Virtual Investor “What This Means” segment">Virtual Investor “What This Means” segment</a>. As part of the segment, Mr. Klemp discussed the Company’s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adult subjects with relapsed or refractory acute myeloid leukemia (R/R AML). Mr. Klemp gave insight into how this milestone triggers the final phase of preparation for the trial’s interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company. The segment is now available for on-demand viewing <a href="https://www.globenewswire.com/Tracker?data=m3wvkghcJspr424sMTW5P7DSIkKN3l3IUI6lekSfHBz-3yZaJ1qQdhDORjGwj3kkVjAioom4_APyEbsc4wbEjyUWsr4aeM4gt-nBt7XGNw8=" rel="nofollow" target="_blank" title="here">here</a>. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.  For more information about the Company, please visit <a href="https://www.globenewswire.com/Tracker?data=p574KX2SQIb2MDrmTMmUbLhqjajEZBD_wNU12Qe6USIcGaFXE-OuhqMhj0BZLY7n9iWh35ieZyDu86YO_9m1yML_qED64PFAYgyg28j7Jos=" rel="nofollow" target="_blank" title="www.moleculin.com">www.moleculin.com</a> and connect on <a href="https://www.globenewswire.com/Tracker?data=caH2m4dSr1aIIqDA06KR0G_gbHk8941m5yUlp7ZAv8eV46dxDiDTb6d14lc7xBSX4IA1QWjWI5buOru7KV1tzg==" rel="nofollow" target="_blank" title="X">X</a>, <a href="https://www.globenewswire.com/Tracker?data=9QADdf797Q7NdxVNLERZl9BLXZNoC9PISZCAnsmg4QiZXIdncGEQh-x6xCi_X44INywgv7y11hjxQqDzudcRVC36uf1PCwzH6aLQegN2YgGLb2tKcjbT-azs0EPj12hE" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=KHYHkLWBAkQwkGt4ZoBO4VpVmiiTWPgo6J02qaaie7wPN78wTRJ-bYzG3W5ArE05BpWtoATllrwIWFA42hY5R0LdOTShq95aYWscEenAQO8=" rel="nofollow" target="_blank" title="Facebook">Facebook</a>. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the expected timing and results of the 45-subject interim data unblinding in the MIRACLE trial, the anticipated clinical milestones set forth above, and the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and other indications. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact: JTC Team, LLC Jenene Thomas (908) 824-0775 <a href="https://www.globenewswire.com/Tracker?data=EOOpISuCMZy5N-GLcgpd8yNx06r6NkF3II7QKV34TWglK_WigK_3AA_gTkr7tcsKHA5Nw0wmYYh7WQtvT524FA==" rel="nofollow" target="_blank" title="MBRX@jtcir.com">MBRX@jtcir.com</a> <img alt="" src='https://ml.globenewswire.com/media/ZjE2MzgyZTQtNTVhNS00OWUzLTk5MDktZDBlMTU0NDVlN2VhLTUwMDEzMzYwNy0yMDI2LTA2LTA0LWVu/tiny/Moleculin-Biotech-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn